1. Home
  2. GIFT vs RLYB Comparison

GIFT vs RLYB Comparison

Compare GIFT & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RDE Inc.

GIFT

RDE Inc.

N/A

Current Price

$1.11

Market Cap

33.1M

ML Signal

N/A

Logo Rallybio Corporation

RLYB

Rallybio Corporation

N/A

Current Price

$0.66

Market Cap

28.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GIFT
RLYB
Founded
1999
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.1M
28.7M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
GIFT
RLYB
Price
$1.11
$0.66
Analyst Decision
Strong Buy
Hold
Analyst Count
1
2
Target Price
$4.00
N/A
AVG Volume (30 Days)
61.0K
167.1K
Earning Date
11-10-2025
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$86,142,442.00
$674,000.00
Revenue This Year
N/A
$17.61
Revenue Next Year
$7.20
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
12.71
52 Week Low
$0.82
$0.22
52 Week High
$2.38
$0.95

Technical Indicators

Market Signals
Indicator
GIFT
RLYB
Relative Strength Index (RSI) 48.84 48.58
Support Level $1.03 $0.58
Resistance Level $1.15 $0.74
Average True Range (ATR) 0.05 0.05
MACD 0.00 -0.01
Stochastic Oscillator 41.67 62.00

Price Performance

Historical Comparison
GIFT
RLYB

About GIFT RDE Inc.

Giftify Inc through its wholly-owned subsidiary, has been in the business of connecting digital consumers, businesses and communities with dining and merchant deal options throughout the United States. The company connects digital consumers, businesses, and communities offering dining and merchant deal options nationwide restaurants, and retailers to customers. The Company buys merchant gift cards from the general public and distributors at a discount and then resells them at a markup.

About RLYB Rallybio Corporation

Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

Share on Social Networks: